Differential effects of tumor necrosis factor-α and CD40L on NF-κB inhibitory proteins IκBα, β and ε and on the induction of the Jun amino-terminal kinase pathway in Ramos Burkitt lymphoma cellsNF

European Cytokine Network

Volumn 16, Issue 4, 2005, Pages 267-276

  Laskov, Reuven ^a   Berger, Nir ^a   Horwitz, Marshall S ^b  

^a HEBREW UNIVERSITY   (Israel)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

B lymphoma; CD40L; IkB proteins; JNK; Signal transduction; TNF

Indexed keywords

CD40 LIGAND; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BURKITT LYMPHOMA; CELL ADHESION; CELL AGGREGATION; CELL STRUCTURE; CELL SURFACE; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; BURKITT LYMPHOMA; CD40 LIGAND; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME INDUCTION; HL-60 CELLS; HUMANS; I-KAPPA B PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MICE; NF-KAPPA B; NIH 3T3 CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845864334     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Wallach D, Varfolomeev EE, Malinin NL, et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 1999; 17: 331.
2. Calderhead DM, Kosaka Y, Manning EM, et al. CD40-CD154 interactions in B-cell signaling. Curr Top Microbiol Immunol 2000; 245: 73.
3. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745.
4. Durandy A, Honjo T. Human genetic defects in class-switch recombination (hyper-IgM syndromes). Curr Opin Immunol 2001; 13: 543.
5. Zan H, Cerutti A, Dramitinos P, et al. Induction of Ig somatic hypermutation and class switching in a human monoclonal IgM+ IgD+ B cell line in vitro: definition of the requirements and modalities of hypermutation. J Immunol 1999; 162: 3437.
6. McHeyzer-Witliams L, Driver DJ, McHeyzer-Williams MG. Germinal center reaction. Curr Opin Hematol 2001; 8: 52.
7. Cook MC, Korner H, Riminton DS, et al. Generation of splenic follicular structure and B cell movement in tumor necrosis factor-deficient mice. J Exp Med 1998; 188: 1503.
8. Ruuls SR, Hoek RM, Ngo VN, et al. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 2001; 15: 533.
9. Kuprash DV, Alimzhanov MB, Tumanov AV, et al. Redundancy in tumor necrosis factor (TNF) and lymphotoxin (LT) signaling in vivo: mice with inactivation of the entire TNF/LT locus versus single-knockout mice. Mol Cell Biol 2002; 22: 8626.
10. Buck C, Digel W, Schoniger W, et al. Tumor necrosis factor-alpha, but not lymphotoxin, stimulates growth of tumor cells in hairy cell leukemia. Leukemia 1990; 4: 431.
11. Lens SM, Tesselaar K, den Drijver BF, van Oers MH, van Lier RA. A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. J Immunol 1996; 156: 507.
12. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 1996; 184: 1397.
13. Corcione A, Ottonello L, Tortolina G, et al. Recombinant tumor necrosis factor enhances the locomotion of memory and naive B lymphocytes from human tonsils through the selective engagement of the type II receptor. Blood 1997; 90: 4493.
14. Okazaki I, Yoshikawa K, Kinoshita K, et al. Activation-induced cytidine deaminase links class switch recombination and somatic hypermutation. Ann N Y Acad Sci 2003; 987: 1.
15. Sale JE, Neuberger MS. TdT-accessible breaks are scattered over the immunoglobulin V domain in a constitutively hypermutating B cell line. Immunity 1998; 9: 859.
16. Faili A, Aoufouchi S, Gueranger Q, et al. AID-dependent somatic hypermutation occurs as a DNA single-strand event in the BL2 cell line. Nat Immunol 2002; 3: 815.
17. Zhang W, Bardwell PD, Woo CJ, et al. Clonal instability of V region hypermutation in the Ramos Burkitt's lymphoma cell line. Int Immunol 2001; 13: 1175.
18. Grammer AC, Swantek JL, McFarland RD, Miura Y, Geppert T, Lipsky PE. TNF receptor-associated factor-3 signaling mediates activation of p38 and Jun N-terminal kinase, cytokine secretion, and Ig production following ligation of CD40 on human B cells. J Immunol 1998; 161: 1183.
19. Dadgostar H, Cheng G. An intact zinc ring finger is required for tumor necrosis factor receptor-associated factor-mediated nuclear factor-kappaB activation but is dispensable for c-Jun N-terminal kinase signaling. J Biol Chem 1998; 273: 24775.
20. Zhu N, Ramirez LM, Lee RL, et al. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. J Immunol 2002; 168: 744.
21. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621.
22. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725.
23. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280.
24. Siebenlist U, Brown K, Claudio E. Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 2005; 5: 435.
25. Liou HC, Sha WC, Scott ML, et al. Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994; 14: 5349.
26. Koyama M, Spicer SS, Schulte BA. Distribution of IkappaB proteins in gastric mucosa and other organs of mouse and gerbil. J Histochem Cytochem 2000; 48: 191.
27. Budde LM, Wu C, Tilman C, et al. Regulation of IkappaBbeta expression in testis. Mol Biol Cell 2002; 13: 4179.
28. Zarnegar B, He JQ, Oganesyan G, et al. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci USA 2004; 101: 8108.
29. Klement JF, Rice NR, Car BD, et al. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol Cell Biol 1996; 16: 2341.
30. Hoffmann A, Levchenko A, Scott ML, et al. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 2002; 298: 1241.
31. Goudeau B, Huetz F, Samson S, et al. IkappaBalpha/IkappaBepsilon deficiency reveals that a critical NF-kappaB dosage is required for lymphocyte survival. Proc Natl Acad Sci USA 2003; 100: 15800.
32. Smahi A, Courtois G, Rabia SH, et al. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 2002; 11: 2371.
33. Grumont RJ, Rourke IJ, O'Reilly LA, et al. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med 1998; 187: 663.
34. Sakata N, Hamelmann E, Siadak AW, et al. Differential regulation of CD40-mediated human B cell responses by antibodies directed against different CD40 epitopes. Cell Immunol 2000; 201: 109.
35. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998; 19: 80.
36. Pomerantz JL, Baltimore D. Two pathways to NF-kappaB. Mol Cell 2002; 10: 693.
37. Dejardin E, Droin NM, Delhase M, et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17: 525.
38. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853.
39. Dadgostar H, Zamegar B, Hoffmann A, et al. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci USA 2002; 99: 1497.
40. Laskov R, Berger N, Scharff MD, Horwitz MS. Tumor necrosis factor-alpha and CD40L modulate cell surface morphology and induce aggregation in Ramos Burkitt's lymphoma cells. Leuk Lymphoma 2006; 47: 507.
41. Staal A, van Wijnen AJ, Birkenhager JC, et al. Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol 1996; 10: 1444.
42. Zou W, Amcheslavsky A, Bar-Shavit Z. CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via Toll-like receptor 9. J Biol Chem 2003; 278: 16732.
43. Berberich I. Shu G. L, Clark EA. Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol 1994; 153: 4357.
44. Minden A, Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1997; 1333: F85.
45. Papa S, Zazzeroni F, Pham CG, et al. Linking JNK signaling to NF-kappaB: a key to survival. J Cell Sci 2004; 117: 5197.
46. Sabapathy K, Hochedlinger K, Nam SY, et al. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell 2004; 15: 713.
47. Natoli G, Costanzo A, Ianni A, et al. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 1997; 275: 200.
48. Li Y, Kang J, Friedman J, Tarassishin L, et al. Identification of a cell protein (FIP-3) as a modulator of NF-kappaB activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis. Proc Natl Acad Sci USA 1999; 96: 1042.
49. Munroe ME, Bishop GA. Role of tumor necrosis factor (TNF) receptor-associated factor 2 (TRAF2) in distinct and overlapping CD40 and TNF receptor 2/CD120b-mediated B lymphocyte activation. J Biol Chem 2004; 279: 53222.
50. Saporito MS, Thomas BA, Scott RW. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem 2000; 75: 1200.
51. Shumway SD, Miyamoto S. A mechanistic insight into a proteasome- independent constitutive inhibitor kappaBalpha (IkappaBalpha) degradation and nuclear factor kappaB (NF-kappaB) activation pathway in WEHI-231 B-cells. Biochem J 2004; 380: 173.
52. O'Connor S, Shumway SD, Amanna IJ, et al. Regulation of constitutive p50/c-Rel activity via proteasome inhibitor-resistant IkappaBalpha degradation in B cells. Mol Cell Biol 2004; 24: 4895.
53. Simeonidis S, Stauber D, Chen G, et al. Mechanisms by which IkappaB proteins control NF-kappaB activity. Proc Natl Acad Sci USA 1999; 96: 49.
54. Fischer C, Page S, Weber M, et al. Differential effects of lipopolysaccharide and tumor necrosis factor on monocytic Kappa kinase signalsome activation and IkappaB proteolysis. J Biol Chem 1999; 274: 24625.
55. Thompson JE, Phillips RJ, Erdjument-Bromage H, et al. I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell 1995; 80: 573.
56. Mizgerd JP, Scott ML, Spieker MR, et al. Functions of IkappaB proteins in inflammatory responses to Escherichia coli LPS in mouse lungs. Am J Respir Cell Mol Biol 2002; 27: 575.
57. Cheshire Jr. JL. Baldwin, AS. Synergistic activation of NF-kappaB by tumor necrosis factor alpha and gamma interferon via enhanced I kappaB alpha degradation and de novo I kappaBbeta degradation. Mol Cell Biol 1997; 17: 6746.
58. Hu X. Proteolytic signaling by TNFalpha: caspase activation and IkappaB degradation. Cytokine 2003; 21: 286.
59. Chen Y, Vallee S, Wu J, et al. Inhibition of NF-kappaB activity by IkappaBbeta in association with kappaB-Ras. Mol Cell Biol 2004; 24: 3048.
60. Han Y, Weinman S, Boldogh I, et al. Tumor necrosis factor-alpha-inducible IkappaBalpha proteolysis mediated by cytosolic m-calpain. A mechanism parallel to the ubiquitin-proteasome pathway for nuclear factor-kappab activation. J Biol Chem 1999; 274: 787.
61. Imbert VR, Rupec A, Livolsi A, et al. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 1996; 86: 787.
62. Kang JL, Pack IS, Hong SM, et al. Silica induces nuclear factor-kappa B activation through tyrosine phosphorylation of I kappa B-alpha in RAW264.7 macrophages. Toxicol Appl Pharmacol 2000; 169: 59.
63. Pierce JW, Schoenleber R, Jesmok G, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997; 272: 21096.
64. Natarajan K, Singh Jr. S, Burke TR, et al. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A 1996; 93: 9090.